Niagen Bioscience is trading now at $3.12, down 5.02%, with sector pressure the primary explanation after no clear company-specific catalyst emerged on August 31, 2026.
- Biotech ETF XBI is down 4.24% during regular trading.
- Broader markets are also lower amid geopolitical tensions, rising oil prices, and renewed concerns about interest rates.
- The latest identified major announcement was the August 4, 2026 second-quarter results.